The evolution of commercial drug delivery technologies
Drug delivery technologies have enabled the development of many pharmaceutical
products that improve patient health by enhancing the delivery of a therapeutic to its target …
products that improve patient health by enhancing the delivery of a therapeutic to its target …
Recent advances and discoveries in the mechanisms and functions of CAR T cells
This Review discusses the major advances and changes made over the past 3 years to our
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
Interleukins in cancer: from biology to therapy
Interleukins and associated cytokines serve as the means of communication for innate and
adaptive immune cells as well as non-immune cells and tissues. Thus, interleukins have a …
adaptive immune cells as well as non-immune cells and tissues. Thus, interleukins have a …
Navigating CAR-T cells through the solid-tumour microenvironment
AJ Hou, LC Chen, YY Chen - Nature reviews Drug discovery, 2021 - nature.com
The adoptive transfer of T cells that are engineered to express chimeric antigen receptors
(CARs) has shown remarkable success in treating B cell malignancies but only limited …
(CARs) has shown remarkable success in treating B cell malignancies but only limited …
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy
Y Tian, D **e, L Yang - Signal transduction and targeted therapy, 2022 - nature.com
Oncolytic viruses (OVs) are emerging as potentially useful platforms in treatment methods for
patients with tumors. They preferentially target and kill tumor cells, leaving healthy cells …
patients with tumors. They preferentially target and kill tumor cells, leaving healthy cells …
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
R Polak, ET Zhang, CJ Kuo - Nature Reviews Cancer, 2024 - nature.com
The development of neoplasia involves a complex and continuous interplay between
malignantly transformed cells and the tumour microenvironment (TME). Cancer …
malignantly transformed cells and the tumour microenvironment (TME). Cancer …
A genome-scale screen for synthetic drivers of T cell proliferation
The engineering of autologous patient T cells for adoptive cell therapies has revolutionized
the treatment of several types of cancer. However, further improvements are needed to …
the treatment of several types of cancer. However, further improvements are needed to …
Recent advances in CAR-T cell engineering
R Huang, X Li, Y He, W Zhu, L Gao, Y Liu… - Journal of hematology & …, 2020 - Springer
Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for
relapsed or refractory tumors, particularly for hematological malignancies. Although the …
relapsed or refractory tumors, particularly for hematological malignancies. Although the …
CAR T cell therapy for solid tumors: bright future or dark reality?
Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to
its success for hematological malignancies in clinical studies leading to the US Food and …
its success for hematological malignancies in clinical studies leading to the US Food and …
Immunogenicity of CAR T cells in cancer therapy
DL Wagner, E Fritsche, MA Pulsipher… - Nature reviews Clinical …, 2021 - nature.com
Patient-derived T cells genetically reprogrammed to express CD19-specific chimeric antigen
receptors (CARs) have shown remarkable clinical responses and are commercially …
receptors (CARs) have shown remarkable clinical responses and are commercially …